Morgan Stanley
MS is still being valued like a mature broker at 15.78x earnings even as wealth scale, an improving banking cycle, and consistent execution are lifting forward earnings power faster than the market is crediting.
Morgan Stanley is being paid for like a good bank, not like the stronger hybrid wealth and markets compounder it has become. At $196.31, the stock sits on 15.78x FY2025 EPS of $10.34. That is only modestly above the 14.7x peer average even though MS has a more balanced mix, better fee density, and clearer operating momentum than many traditional capital-markets peers. The market is still treating parts of the recent earnings step-up as cyclical. The case here is that more of it is structural.
The first pillar is Wealth. This segment is no longer just ballast. It is a scaled earnings engine with $10T of client assets, record quarterly revenue of $8.9B, and $148B of quarterly net new assets. Those numbers matter because they create recurring fee streams, improve deposit and lending economics, and deepen cross-sell into workplace, alternatives, and advisory channels. Management also guided that Q3 wealth NII should rise sequentially, which is notable in a business that had previously been pressured by rate expectations. If Wealth can keep compounding, firm earnings become less dependent on episodic trading spikes.
The second pillar is that capital markets are still in recovery, not at peak. Management said, "The investment banking outlook is constructive. Pipelines are healthy." Institutional Securities already produced $11B of Q2 revenue and $4.3B of pre-tax profit before sponsor activity is fully back. That leaves room for upside if M&A, underwriting, and IPO issuance continue broadening in 2027. The 2024 view that the firm was in a multi-year recovery has held up, even if the path has been slower than hoped in some pockets.
The third pillar is execution. Eight consecutive EPS beats, including a +19.7% beat in the latest quarter, deserve credit. So does capital discipline: $1.5B of buybacks in Q2, a 15% dividend hike, and 14.8% CET1 at the same time. What keeps conviction at Medium, not High, is that leverage is still substantial and some margin strength may normalize. But at this price, the stock does not fully reflect another year of wealth-led growth plus a still-rising banking cycle.
IPO and M&A activity reopen more fully, sponsor demand snaps back, Wealth sustains outsized net new assets, and earnings compounding drives both estimate revisions and multiple expansion.
Wealth fees and NII keep rising, investment banking pipelines convert through 2H26 and 2027, and MS earns a modest premium to peers on better franchise mix and execution.
Capital markets recovery slips, sponsor activity stays muted, trading cools after a strong first half, and earnings fail to build enough to defend the current mid-teens multiple.
Quant call aligns with analyst consensus (Buy: 7 buy / 5 hold / 1 sell).
Never, ever invest in the present.
Forward earnings power looks better than the trailing multiple implies. On FY2025 EPS of $10.34, the stock trades at 15.78x, but current run-rate profitability, healthy banking pipelines, and sequentially improving wealth NII suggest the next 12 to 24 months can support a higher earnings base than trailing numbers alone capture. The moat is stronger now than it was three years ago because $10T of client assets, advisor distribution, and cross-selling across Wealth, Institutional Securities, and Investment Management make the franchise harder to dislodge, while AI is more likely to enhance advisor productivity, risk management, and operating efficiency than disrupt the core relationship model. Regulation remains a permanent constraint on leverage and capital return, but with 14.8% CET1 and at least a 300 bps cushion, MS has room to keep investing and returning capital while taking share in a broadening capital-markets cycle.
- FY2025 EPS of $10.34, up 43.1% YoY, with 46.9% operating margin, shows earnings power has stepped up materially.
- Q2 2026 revenue of $21.3B and EPS ex-CVA of $3.46 were records, while Institutional Securities produced $11B of revenue and $4.3B of pre-tax profit.
- Capital return remains active, with the quarterly dividend raised 15% to $1.15 and $1.5B of buybacks completed in the quarter, backed by a 14.8% CET1 ratio.
- Wealth keeps compounding the franchise. The firm now has $10T client assets, Q2 wealth revenue hit a record $8.9B, and $148B of net new assets in the quarter supports fee growth beyond rate sensitivity.
- Capital markets are recovering into MS strength. Management said, "The investment banking outlook is constructive. Pipelines are healthy." That matters because Institutional Securities already delivered $11B of quarterly revenue before sponsor activity is fully back.
- Execution quality is high and visible. MS has beaten consensus EPS in 8 straight quarters, with the last four beats of +33.3%, +10.3%, +13.6%, and +19.7%.
- Valuation is not demanding for the current trajectory. The stock trades at 15.78x earnings versus peer average 14.7x, a small premium for materially better diversification and wealth scale, while the engine's blended target is $253, or 28.9% upside.
- Some of the FY2025 margin profile looks peak-ish. Reported operating margin jumped to 46.9% from 17.1% in the prior year, and Q2 2026 EBITDA margin was only 21.3%, down 200 bps q/q, which argues against assuming linear margin expansion.
- Balance-sheet leverage is inherent and high. Debt/equity is 4.75 and debt/EBITDA is 19.71, so even with strong capital ratios the model remains exposed to funding and market stress if conditions tighten.
- Free cash flow is mixed in the data set. FY2025 FCF is shown at -$3.6B, while deep-dive cash flow shows $3.6B, which limits confidence in cash conversion and makes capital return more balance-sheet dependent than a pure fee model would be.
- Trading and marks can still swing quarterly results. Other revenues were -$152M in Q2 from mark-to-market losses on corporate loans held for sale, and management said commodities moderated after an exceptionally strong Q1.
| Metric | Value | Context |
|---|---|---|
| Current price | $196.31 | Reference price for valuation and scenario framing |
| Quant price target | $253 | 28.9% upside, Medium confidence, earnings_growth_blend |
| FY2025 revenue | $115.0B | 9.0% YoY growth |
| FY2025 EPS | $10.34 | 43.1% YoY growth |
| FY2025 operating margin | 46.9% | Versus 17.1% in prior FY |
| Net margin | 22.5% | Healthy profitability despite market-sensitive mix |
| P/E | 15.78x | Above peer average 14.7x |
| P/S | 2.44x | Below peer average 4.7x |
| Balance sheet capital | CET1 14.8% | At least 300 bps cushion per management |
| Capital return | $1.15 quarterly dividend, $1.5B Q2 buybacks | Dividend raised 15% |
| Earnings track record | 8 straight beats | Latest beat $3.46 vs $2.89, or +19.7% |
| 52-week position | -16.2% vs high, 1.4% above 200-day average | Pullback has improved entry without breaking long-term trend |
The biggest risk is that the banking recovery stalls while trading normalizes, because the stock at 15.78x earnings leaves less room for error if healthy pipelines fail to convert into fees and mark-to-market items like the recent -$152M loan-related hit persist.
The next catalyst is Q3 earnings on October 14, 2026, especially whether Wealth NII delivers the guided modest sequential increase and whether investment banking fees confirm the constructive 2H outlook.
Ownership is tightly held, with the top 3 institutions at 57.1% and insiders at 24.1%, which limits float churn and usually dampens speculative dislocations. Short interest is only 1.23%, or 14.7M shares with 2.7 days-to-cover, so this is not a squeeze story. Options positioning is less friendly near term because the negative GEX regime and zero-gamma at $206.06 suggest choppier trading until the stock regains that level, which helps explain why the setup is better than the tape despite the recent -9.44% one-month drawdown.
Record quarter driven by equities, stronger investment banking activity, and solid client engagement, though commodities moderated sequentially.
Record revenue with $148B net new assets, fee-based growth, and expected modest sequential NII increase in Q3.
Smaller earnings contributor, but supported by the broader $10T client asset ecosystem and alternatives and solutions capabilities.
Record quarter with constructive 2H momentum across IB, wealth and markets.
Execution has been strong and mostly consistent with what management laid out on the 2024 Q3 call. Two years ago management said, "Pipelines are healthy and diverse. We continue to believe we are in the early stages of a multi-year capital markets recovery." Since then, quarterly EPS moved from $1.88 in 2024 Q3 to $3.46 in 2026 Q2, and MS delivered 8 straight EPS beats, including +19.0% in 2024 Q3 and +19.7% in 2026 Q2. The wealth strategy also translated into numbers: the old long-term $10T client asset target has now been reached, while wealth revenue rose from $7.3B in 2024 Q3 to $8.9B in 2026 Q2. On capital return, Ted Pick said in 2024, "We'll be buying back $3 billion-plus this year," and the firm has continued repurchases, including $1.5B in the latest quarter, while lifting the dividend from $0.925 then to $1.15 now. The only partial miss is timing, because management was right on recovery direction but sponsor activity and full IPO normalization are still not fully back, which means the cycle is real but slower than the most bullish versions of the thesis assumed.
For the third quarter, we expect a modest sequential increase in NII.
We continue to expect our annual tax rate to be between 22% and 23%, which similar to prior years, will exhibit some quarterly volatility.
The investment banking outlook is constructive. Pipelines are healthy.
In the second quarter, Morgan Stanley again delivered top-line and bottom-line record results, with revenues exceeding $21 billion and EPS of $3.46, marking an exceptional first half for 2026.
I would tell you right now, the bias continues to be to go organic.
The moat sits in distribution, client entrenchment, and balance-sheet credibility. $10T of client assets, a scaled advisor network, and a top-tier institutional franchise create a closed loop where Wealth gathers assets, Markets monetizes client activity, and Banking captures strategic transactions. That advantage is durable over the next 3 to 5 years because AI should improve advisor efficiency, compliance, and personalization at firms with scale, and smaller competitors will struggle to match the tech spend and data breadth without compressing returns.
Capital deployment looks disciplined. Management completed $1.5B of buybacks in Q2, raised the dividend 15% to $1.15 per share, and still held 14.8% CET1, which management described as at least a 300 bps capital cushion. The stated bias, "the bias continues to be to go organic," is sensible here because incremental investment in advisors, workplace channels, and AI tools likely earns better returns than large M&A.
MS rates a BUY at Medium conviction. The stock is not cheap enough for complacency, but it is cheap enough for the current earnings path, especially if Wealth keeps compounding and banking activity continues to recover. The setup is helped by strong execution, active capital return, and a price still 16.2% below the high after a recent pullback. The call would weaken if Q3 fails to show the guided Wealth NII improvement or if healthy pipelines do not translate into fee revenue over the next two quarters. Until then, the path to $253 looks more plausible than fully priced.
≣ Full research note tap to expand
Executive Summary
BUY, Medium conviction. Rated BUY, Medium conviction. Morgan Stanley has put up eight straight EPS beats, FY2025 EPS grew 43.1% to $10.34, and the latest quarter showed record results across Institutional Securities and Wealth with $10T of client assets now in the system. At $196.31, or 16.2% below the 52 week high, the stock offers upside to the $253 base case if management converts healthy investment banking pipelines and wealth flows into another leg of earnings growth.
Investment Thesis
Morgan Stanley is being paid for like a good bank, not like the stronger hybrid wealth and markets compounder it has become. At $196.31, the stock sits on 15.78x FY2025 EPS of $10.34. That is only modestly above the 14.7x peer average even though MS has a more balanced mix, better fee density, and clearer operating momentum than many traditional capital-markets peers. The market is still treating parts of the recent earnings step-up as cyclical. The case here is that more of it is structural.
The first pillar is Wealth. This segment is no longer just ballast. It is a scaled earnings engine with $10T of client assets, record quarterly revenue of $8.9B, and $148B of quarterly net new assets. Those numbers matter because they create recurring fee streams, improve deposit and lending economics, and deepen cross-sell into workplace, alternatives, and advisory channels. Management also guided that Q3 wealth NII should rise sequentially, which is notable in a business that had previously been pressured by rate expectations. If Wealth can keep compounding, firm earnings become less dependent on episodic trading spikes.
The second pillar is that capital markets are still in recovery, not at peak. Management said, "The investment banking outlook is constructive. Pipelines are healthy." Institutional Securities already produced $11B of Q2 revenue and $4.3B of pre-tax profit before sponsor activity is fully back. That leaves room for upside if M&A, underwriting, and IPO issuance continue broadening in 2027. The 2024 view that the firm was in a multi-year recovery has held up, even if the path has been slower than hoped in some pockets.
The third pillar is execution. Eight consecutive EPS beats, including a +19.7% beat in the latest quarter, deserve credit. So does capital discipline: $1.5B of buybacks in Q2, a 15% dividend hike, and 14.8% CET1 at the same time. What keeps conviction at Medium, not High, is that leverage is still substantial and some margin strength may normalize. But at this price, the stock does not fully reflect another year of wealth-led growth plus a still-rising banking cycle.
Key Metrics
| Metric | Value | Context |
|---|---|---|
| Current price | $196.31 | Reference price for valuation and scenario framing |
| Quant price target | $253 | 28.9% upside, Medium confidence, earnings_growth_blend |
| FY2025 revenue | $115.0B | 9.0% YoY growth |
| FY2025 EPS | $10.34 | 43.1% YoY growth |
| FY2025 operating margin | 46.9% | Versus 17.1% in prior FY |
| Net margin | 22.5% | Healthy profitability despite market-sensitive mix |
| P/E | 15.78x | Above peer average 14.7x |
| P/S | 2.44x | Below peer average 4.7x |
| Balance sheet capital | CET1 14.8% | At least 300 bps cushion per management |
| Capital return | $1.15 quarterly dividend, $1.5B Q2 buybacks | Dividend raised 15% |
| Earnings track record | 8 straight beats | Latest beat $3.46 vs $2.89, or +19.7% |
| 52-week position | -16.2% vs high, 1.4% above 200-day average | Pullback has improved entry without breaking long-term trend |
Financial Strength
The balance sheet read is better than the raw leverage ratios suggest, but it is still a leveraged financial and should be treated that way. Debt metrics, 4.75x debt/equity and 19.71x debt/EBITDA, look heavy in isolation, yet capital is solid with 14.8% CET1 and a stated 300 bps cushion, which supports client activity and shareholder returns at the same time. Profitability is strong, with 22.5% net margin and sharply improved FY2025 operating margin, but the quarter also showed that markets businesses do not move in a straight line, as EBITDA margin fell to 21.3% from 23.3% sequentially. Overall, this is a financially sound franchise for its business model, though not one that deserves balance-sheet complacency.
Competitive Position
The moat sits in distribution, client entrenchment, and balance-sheet credibility. $10T of client assets, a scaled advisor network, and a top-tier institutional franchise create a closed loop where Wealth gathers assets, Markets monetizes client activity, and Banking captures strategic transactions. That advantage is durable over the next 3 to 5 years because AI should improve advisor efficiency, compliance, and personalization at firms with scale, and smaller competitors will struggle to match the tech spend and data breadth without compressing returns.
Management & Guidance
Current guidance is favorable and credible. Sharon Yeshaya said, "For the third quarter, we expect a modest sequential increase in NII," and, "The investment banking outlook is constructive. Pipelines are healthy." Those statements are backed by hard evidence in the latest quarter: record $21.3B revenue, $11B in Institutional Securities revenue, and record $8.9B Wealth revenue with $148B of net new assets. Credibility is high because management has now posted 8 consecutive EPS beats, although the market should still watch whether sponsor activity, which management says is not fully back, actually converts into realized fees rather than remaining a deferred recovery narrative.
Segment Analysis
- Institutional Securities ($11.0B in Q2 2026 revenue, about 51.6% of quarterly firm revenue): Record quarter driven by equities, stronger investment banking activity, and solid client engagement, though commodities moderated sequentially.
- Wealth Management ($8.9B in Q2 2026 revenue, about 41.8% of quarterly firm revenue): Record revenue with $148B net new assets, fee-based growth, and expected modest sequential NII increase in Q3.
- Investment Management and other (Implied remainder of about 6.6% of Q2 2026 firm revenue): Smaller earnings contributor, but supported by the broader $10T client asset ecosystem and alternatives and solutions capabilities.
Capital Allocation
Capital deployment looks disciplined. Management completed $1.5B of buybacks in Q2, raised the dividend 15% to $1.15 per share, and still held 14.8% CET1, which management described as at least a 300 bps capital cushion. The stated bias, "the bias continues to be to go organic," is sensible here because incremental investment in advisors, workplace channels, and AI tools likely earns better returns than large M&A.
Management Execution & Track Record
Execution has been strong and mostly consistent with what management laid out on the 2024 Q3 call. Two years ago management said, "Pipelines are healthy and diverse. We continue to believe we are in the early stages of a multi-year capital markets recovery." Since then, quarterly EPS moved from $1.88 in 2024 Q3 to $3.46 in 2026 Q2, and MS delivered 8 straight EPS beats, including +19.0% in 2024 Q3 and +19.7% in 2026 Q2. The wealth strategy also translated into numbers: the old long-term $10T client asset target has now been reached, while wealth revenue rose from $7.3B in 2024 Q3 to $8.9B in 2026 Q2. On capital return, Ted Pick said in 2024, "We'll be buying back $3 billion-plus this year," and the firm has continued repurchases, including $1.5B in the latest quarter, while lifting the dividend from $0.925 then to $1.15 now. The only partial miss is timing, because management was right on recovery direction but sponsor activity and full IPO normalization are still not fully back, which means the cycle is real but slower than the most bullish versions of the thesis assumed.
Positioning & Flows
Ownership is tightly held, with the top 3 institutions at 57.1% and insiders at 24.1%, which limits float churn and usually dampens speculative dislocations. Short interest is only 1.23%, or 14.7M shares with 2.7 days-to-cover, so this is not a squeeze story. Options positioning is less friendly near term because the negative GEX regime and zero-gamma at $206.06 suggest choppier trading until the stock regains that level, which helps explain why the setup is better than the tape despite the recent -9.44% one-month drawdown.
Bull Case
- Wealth keeps compounding the franchise. The firm now has $10T client assets, Q2 wealth revenue hit a record $8.9B, and $148B of net new assets in the quarter supports fee growth beyond rate sensitivity.
- Capital markets are recovering into MS strength. Management said, "The investment banking outlook is constructive. Pipelines are healthy." That matters because Institutional Securities already delivered $11B of quarterly revenue before sponsor activity is fully back.
- Execution quality is high and visible. MS has beaten consensus EPS in 8 straight quarters, with the last four beats of +33.3%, +10.3%, +13.6%, and +19.7%.
- Valuation is not demanding for the current trajectory. The stock trades at 15.78x earnings versus peer average 14.7x, a small premium for materially better diversification and wealth scale, while the engine's blended target is $253, or 28.9% upside.
Bear Case
- Some of the FY2025 margin profile looks peak-ish. Reported operating margin jumped to 46.9% from 17.1% in the prior year, and Q2 2026 EBITDA margin was only 21.3%, down 200 bps q/q, which argues against assuming linear margin expansion.
- Balance-sheet leverage is inherent and high. Debt/equity is 4.75 and debt/EBITDA is 19.71, so even with strong capital ratios the model remains exposed to funding and market stress if conditions tighten.
- Free cash flow is mixed in the data set. FY2025 FCF is shown at -$3.6B, while deep-dive cash flow shows $3.6B, which limits confidence in cash conversion and makes capital return more balance-sheet dependent than a pure fee model would be.
- Trading and marks can still swing quarterly results. Other revenues were -$152M in Q2 from mark-to-market losses on corporate loans held for sale, and management said commodities moderated after an exceptionally strong Q1.
Valuation & Price Target
Engine price target $253 (+28.9% vs current), Medium confidence.
- P/E Multiple: $235.53 (28% weight)
- PEG (growth-adjusted): $223.92 (20% weight)
- P/S Multiple: $460.42 (11% weight)
- Quality-adjusted: $249.33 (20% weight)
- DCF: $5.12 (4% weight)
This rating aligns with the quant baseline BUY and the $253 price target. The main reason not to upgrade conviction to High is that some of the recent earnings strength reflects favorable market conditions and trading intensity, while reported leverage remains high at 4.75x debt/equity and cash-flow reporting is mixed. Still, the numbers support the positive call: 43.1% EPS growth in FY2025, record $21.3B Q2 revenue, 8 straight beats, 14.8% CET1, and a stock still 16.2% below its high. Analyst consensus is also Buy, but that is only a cross-check, not the basis for the call.
Risk Assessment
Risk score 28/100 (Low). The biggest risk is that the banking recovery stalls while trading normalizes, because the stock at 15.78x earnings leaves less room for error if healthy pipelines fail to convert into fees and mark-to-market items like the recent -$152M loan-related hit persist.
The Bottom Line
MS rates a BUY at Medium conviction. The stock is not cheap enough for complacency, but it is cheap enough for the current earnings path, especially if Wealth keeps compounding and banking activity continues to recover. The setup is helped by strong execution, active capital return, and a price still 16.2% below the high after a recent pullback. The call would weaken if Q3 fails to show the guided Wealth NII improvement or if healthy pipelines do not translate into fee revenue over the next two quarters. Until then, the path to $253 looks more plausible than fully priced.
Go deeper in the app
Live charts, options analytics, the full earnings-call breakdown, price alerts, and every other stock — updated in real time.
Get Tickr